Streamlining Radioembolization for CCC and Metastatic Liver Cancer

Recruiting Observational Study
Metastatic Colorectal Carcinoma (mCRC) Metastatic Liver Cancer Cholangiocarcinoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
19 and older
Sex
Any
Study type
Observational
Participants needed
60 (estimated)
Sponsor
Seoul National University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
TARE uses radioactive microspheres (20-60 μm), which are trapped in tumors due to abnormal vasculature, while normal liver sinusoids (≤15 μm) prevent their passage. However, some microspheres may drain into hepatic veins and reach the lungs, risking radiation pneumonitis. Pre-procedural evaluation with angiography and nuclear imaging (MAA scan with SPECT/CT) is required to calculate lung shunt fra…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Adult aged 19 and over * metastatic liver cancer or cholangiocarcinoma * the diameter of the largest tumor ≤ 7cm, tumor number 5 or less * FLR volume \> 30% of total non-tumorous liver volume * Dysmorphic intratumoral vessel : absent, if present, 3mm or…
Contacts

Hyo-Cheol Kim, MD

82-10-5136-5205

radioembolization@snu.ac.kr

CONTACT